Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.68 +1.24 (+2.36%)

Streaming Delayed Price Updated: 9:58 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 Next >

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

December 16, 2025

Issued on behalf of Avant Technologies Inc.

From USA News Group

Via GlobeNewswire

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

September 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

Via Investor Brand Network

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

July 11, 2024

Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.

Via MarketBeat

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

March 20, 2024

Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel

Via MarketBeat

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

March 06, 2024

Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place

Via MarketBeat

MarketBeat Week in Review – 2/26 - 3/1

March 02, 2024

As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest

Via MarketBeat

Topics Economy Stocks

bluebird bio: How to play LEAPS options for growth and income

February 27, 2024

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT

Via MarketBeat

Is CRISPR Therapeutics the NVIDIA of gene editing?

February 26, 2024

CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv

Via MarketBeat

Topics Artificial Intelligence

Gene therapy: Why does it cost millions for a single treatment?

February 15, 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.

Via MarketBeat

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

These 5 growth stocks are now in buy ranges

January 25, 2024

Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs.

Via MarketBeat

Topics ETFs

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Via MarketBeat

2 low-priced gene therapy stocks to speculate on

January 08, 2024

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe

Via MarketBeat

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Via MarketBeat

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

December 08, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

November 16, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Why you can make Vertex Pharmaceuticals a buy on any pullback

November 08, 2023

Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely

Via MarketBeat

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Flee to Healthcare Stocks if Recession Rears its Head?

September 20, 2023

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

Via MarketBeat

Topics Economy

3 Biotech Stocks to Buy for Long-Term Gains

July 13, 2023

The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.

Via MarketBeat

Topics ETFs Economy

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

June 09, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

June 08, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings

May 18, 2023

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

Via MarketBeat

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

April 03, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

March 27, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

December 10, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Shares Higher On Optimism About CRISPR Partnership

October 05, 2022

Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments.

Via MarketBeat

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.